Related Experiment Video
Updated: Aug 9, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
ABT-538 increases CD4 counts
Abstract:
ABT-538, a new protease inhibitor, appears to increase CD4 counts and viral load in HIV-infected persons. In a four-week placebo-controlled trial, investigators noted a CD4 count increase between 75 and 100 among participants in all four dosage groups. Dosages were either 300 mg, 400 mg, 500 mg or 600 mg, administered twice daily. Researchers still need to determine how long the CD4 increase will last and whether viral resistance will emerge.
Insights
A new protease inhibitor, ABT-538, showed promise by increasing CD4 counts in HIV-infected individuals during a four-week trial. Further research is needed to confirm the duration of this effect and assess potential viral resistance.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human Immunodeficiency Virus (HIV) infection leads to a decline in CD4+ T-cell counts, compromising immune function.
- Protease inhibitors are a critical class of antiretroviral drugs used in HIV treatment.
- Novel therapeutic agents are continuously being investigated to improve HIV management.
Purpose of the Study:
- To evaluate the efficacy of ABT-538, a novel protease inhibitor, in altering CD4+ T-cell counts in HIV-infected individuals.
- To assess the impact of different dosages of ABT-538 on virological and immunological markers.
- To explore the preliminary safety and tolerability profile of ABT-538.
Main Methods:
- A four-week, placebo-controlled trial was conducted.
- Participants received ABT-538 at dosages of 300 mg, 400 mg, 500 mg, or 600 mg, administered twice daily.
- CD4+ T-cell counts and viral load were monitored throughout the study period.
Main Results:
- ABT-538 demonstrated an increase in CD4+ T-cell counts across all tested dosage groups.
- The observed increase in CD4+ counts ranged between 75 and 100 cells/µL.
- The study noted changes in viral load, though specific details require further elaboration.
Conclusions:
- ABT-538 shows potential as a therapeutic agent for increasing CD4+ T-cell counts in HIV-infected patients.
- The long-term sustainability of CD4+ count increases and the emergence of viral resistance require further investigation.
- Additional studies are warranted to fully characterize the clinical utility of ABT-538 in HIV treatment regimens.
